Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 12;6(7):2120-2128.
doi: 10.1182/bloodadvances.2021004269.

Impact of comorbidity in older patients with peripheral T-cell lymphoma: an international retrospective analysis of 891 patients

Monica Mead  1 , Henrik Cederleuf  2 , Maja Björklund  3 , Xiaoyan Wang  4 , Thomas Relander  5 , Mats Jerkeman  2 , Daria Gaut  6 , Sarah Larson  1 , Fredrik Ellin  2   7
Affiliations

Impact of comorbidity in older patients with peripheral T-cell lymphoma: an international retrospective analysis of 891 patients

Monica Mead et al. Blood Adv. .

Abstract

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive neoplasms with poor outcomes, commonly affecting older patients with comorbidities. This study aims to describe outcomes of older patients with PTCL in a large international cohort. Patients aged ≥70 years with PTCL diagnosed from 1 January 2010 to 31 December 2015 in the Swedish Lymphoma Registry (SLR) and California Cancer Registry (CCR) were identified. Data on comorbidity were retrospectively collected according to the Charlson Comorbidity Index (CCI), and clinical outcomes were extracted. A total of 891 patients were included (SLR, n = 173; CCR, n = 718). Median age was 77 (SLR) and 78 (CCR) years. Included subtypes were as follows: angioimmunoblastic T-cell lymphoma, n = 226; anaplastic large-cell lymphoma, n = 122; enteropathy-associated T-cell lymphoma (EATL), n = 31; hepatosplenic TCL, n = 7; natural killer-/T-cell lymphoma, n = 62; PTCL not otherwise specified, n = 443. CCI data were available in 775 patients (87%), and CCI scores were divided into the groups CCI = 0 (39%), CCI = 1 (22%), and CCI > 1 (39%). Median age did not differ among the CCI groups (P = .72). Patients with a CCI > 1 had a worse median overall survival (4.4 months) compared with patients with CCI = 0 (11.9 months) and CCI = 1 (8.4 months; P < .001). Comorbidity and advancing age in as little as 5-year increments are important adverse factors in this group. Most patients died of lymphoma within a year from diagnosis, underscoring the importance of developing new treatments.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1.
Figure 1.
OS in PTCL according to CCI group. OS of 775 patients ≥70 years with PTCL according to CCI group. CCI = 0, n = 304; CCI = 1, n = 167; CCI > 1, n = 304.
Figure 2.
Figure 2.
OS in patients with PTCL according to age. OS in 891 patients ≥70 years with PTCL according to (A) 5-year age groups (70-74, n = 265; 75-79, n = 257; 80-84, n = 190; 85-89, n = 128; >89, n = 52) and (B) 3 different age groups (70-74, n = 265; 75-84, n = 447; >84, n = 180).
Figure 3.
Figure 3.
OS in nodal PTCL according to histologic subtype. OS of 787 patients ≥70 years with PTCL according to histologic subtype. AITL, n = 226; ALCL, n = 121; PTCL, NOS, n = 440.
Figure 4.
Figure 4.
OS for patients with PTCL receiving multiagent treatment, according to CCI group. OS according to CCI group in 369 patients ≥70 years with PTCL receiving multiagent treatment. CCI = 0, n = 150; CCI = 1, n = 83; CCI > 1, n = 136. extranodal natural killer/T-cell lymphoma patients excluded.
See this image and copyright information in PMC

References

    1. Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project . International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124-4130. - PubMed
    1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390. - PMC - PubMed
    1. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15(10):1467-1475. - PubMed
    1. Ellin F, Landström J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124(10):1570-1577. - PubMed
    1. Moskowitz AJ, Lunning MA, Horwitz SM. How I treat the peripheral T-cell lymphomas. Blood. 2014;123(17):2636-2644. - PMC - PubMed

Publication types